I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Ever since drug-eluting stents (DES) have become widely used in percutaneous coronary intervention (PCI), efficacy and safety of different types of DES have always been an area of clinical attention. Second-generation DES (G2-DES), represented by zotarolimus-eluting stents and cobalt-chromium everolimus-eluting stents, exhibit improved stability and lipotropism of eluting drugs compared with first-generation DES (G1-DES).\[[@ref1][@ref2][@ref3]\] Furthermore, improvements in the polymer biocompatibility coupled with a well-proportioned and slim frame help to reduce endothelial damage and proliferation.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\] Many trials demonstrate that the improved properties of G2-DES results in therapeutic benefits for stable coronary artery disease (SCAD) patients.\[[@ref1][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] A recent network meta-analysis by Windecker *et al*. incorporating hundreds of trials showed that percutaneous transluminal coronary angioplasty (PTCA), bare-metal stent (BMS), and G1-DES all failed to significantly reduce mortality in SCAD patients undergoing PCI while G2-DES significantly reduced all-cause mortality, and decreased risks of revascularization, recurrent myocardial infarction (MI), and stent thrombosis (ST) compared to optimal drug therapy, affording benefits approaching that of the much more invasive coronary artery bypass graft (CABG).\[[@ref16]\] However, for economic reasons, G1-DES is still applied in local hospitals throughout our country. This study evaluated the efficacy and safety of G1-DES and G2-DES in patients with SCAD, by analyzing 2-year follow-up results of a large sample from a single PCI center in China.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

As a retrospective study and data analysis were performed anonymously, this study was exempt from the ethical approval and informed consent from patients.

Study population {#sec2-2}
----------------

For this retrospective, observational study, we identified a consecutive group of 10,724 patients with coronary artery disease (CAD) who had either received PCI or PTCA throughout 2013 in our specialized hospital, Beijing. We excluded patients without a SCAD diagnosis according to criteria based on the "2013 ESC guidelines on the management of SCAD."\[[@ref17]\] Additional exclusion criteria include: (1) patients who received only PTCA without stents implantation; (2) patients who received neither G1-DES nor G2-DES, or received multiple types of stents concurrently; and (3) patients who were diagnosed with acute MI or unstable angina pectoris. Totally 2709 patients were enrolled, including 2152 patients with SCAD and 557 patients with asymptomatic myocardial ischemia. All patients received either G1-DES (*n* = 863) or G2-DES (*n* = 1846) \[[Figure 1](#F1){ref-type="fig"}\]. If patients received PCI treatment in multiple stages due to multivessel disease, we combined the data from all phases of treatment. G1-DES included sirolimus-eluting stents (Partner, Lepu Medical, China; Firebird, MicroPort Medical, China), paclitaxel-eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2-DES included zotarolimus-eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus-eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA), and domestic sirolimus-eluting stents (Firebird2, MicroPort Medical, China).

![The flowchart of this study. CAD: Coronary artery disease. PCI: Percutaneous coronary intervention. PTCA: Percutaneous transluminal coronary angioplasty. DES: Drug-eluting stents.](CMJ-130-1654-g001){#F1}

Procedural details {#sec2-3}
------------------

Patients all received elective PCI treatment after admission. Preoperative oral treatment included aspirin 100 mg/d and clopidogrel loading dose of 300 mg or cumulative dose of 300 mg followed by 75 mg/d. All patients were to take aspirin 100 mg/d indefinitely and clopidogrel 75 mg/d for at least 1 year after stent implantation. Before coronary angiography (CAG), 3000 U heparin sodium was administered through an arterial sheath or intravenously. Before PCI, 100 U/kg of heparin sodium was administered. The dose was lowered to 50--70 U/kg in patients over the age of seventy to reduce bleeding risk. If PCI proceeded for more than 1 h, an additional 1000 U of heparin sodium was administered. Results of CAG were read by experienced cardiologists. More than 50% stenosis of left main artery, left anterior descending artery (LAD), left circumflex artery (LCX), right coronary artery, and main branch of these vessels was defined as coronary artery stenosis. More than 70% stenosis of the vessels mentioned above was indicated for coronary stent implantation. Implantation of G1-DES or G2-DES was decided in consequence of an agreement between our cardiologists and patients, depending on economic factors, including price and insurance.

Follow-up and definitions {#sec2-4}
-------------------------

The average follow-up was 874.9 days. The patients were visited 30 days, 6 months after PCI and every 1 year thereafter. Totally 2682 patients (99.0%) have completed 2-year follow-up in this study. Information of in-hospital outcome was obtained through review of medical records, and the long-term clinical outcome was collected from survey completed by telephone follow-up, follow-up letter or visit. A group of independent clinical physicians was in charge of checking and confirming all adverse events carefully. Investigators training, blinded questionnaire filling, and telephone recording were performed to control the data quality. Primary efficacy endpoints were all major adverse coronary events (MACEs) as well as individual events, including target vessel-related MI (TV-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and cardiogenic death. TV-MI is clearly diagnosed as newly occurring MI, which is either confirmed by CAG that the lesion of target vessel exists, such as severe stenosis, total occlusion, or thrombosis, or showed by electrocardiogram that the new abnormal ST segment and/or T-wave changes related to the target vessel. TVR is defined as revascularization for a new lesion of the target vessel, including PCI or CABG. TLR is defined as revascularization for a new lesion at or within 5 mm from the location of the previously implanted stent. Cardiogenic death is identified as death caused by MI, heart failure, and/or malignant arrhythmia definitely; or death which cannot be explained clearly by other reasons. Primary safety endpoint was defined as definite or probable ST based on the Academic Research Consortium criteria, excluding indefinite ST.

Statistical analysis {#sec2-5}
--------------------

Independent *t*-tests were used to compare continuous variables fitting normal distribution while Chi-square tests were applied to compare categorical variables between the two groups. Propensity score matching (PSM) using closest match with a 1:1 ratio was applied using SPSS 22.0 (IBM Corp., Armonk, New York, USA) to control for baseline differences. *T*-test, Chi-square test, Kaplan--Meier analysis, and multivariate Cox proportional hazard regression analysis were applied using SPSS 22.0 (IBM Corp., Armonk, New York, USA). Covariates for Cox regression were those variables with significant differences in baseline or important clinical meaning. All *P* values were two-sided with a significance level of 0.05. Tendency of significant difference was judged when 0.05 \< *P* \< 0.1.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Of 2709 total patients enrolled, 863 received G1-DES and 1846 received G2-DES. There were significant differences in the baseline levels of hypertension, old MI, lesions involving LAD or LCX, number of lesions treated, number of stents, number of target vessel, thrombolysis in MI flow before PCI, B2, or C lesions, chronic total occlusion lesions, and bifurcation lesions between the two groups \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\]. PSM was applied to control these differences. The two groups were effectively equalized after PSM with 833 patients selected from each group \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Clinical baseline data before and after propensity score matching

  Characteristics                            Before PSM    Statistics    *P*        After PSM   Statistics    *P*                      
  ------------------------------------------ ------------- ------------- ---------- ----------- ------------- ------------- ---------- -------
  Age (years)                                58.2 ± 9.9    58.0 ± 10.1   0.453\*    0.651       58.2 ± 9.9    58.2 ± 10.2   −0.110\*   0.913
  Sex (male)                                 658 (76.2)    1436 (77.8)   0.799^†^   0.371       634 (76.1)    643 (77.2)    0.272^†^   0.602
  BMI (kg/m^2^)                              26.0 ± 3.2    26.0 ± 3.2    0.163\*    0.870       26.0 ± 3.2    26.0 ± 3.2    0.397\*    0.691
  LVEF (%)                                   63.0 ± 6.9    63.9 ± 7.0    −3.065\*   0.002       63.0 ± 7.0    62.9 ± 7.8    0.349\*    0.727
  Hypertension                               582 (67.4)    1157 (62.7)   5.804^†^   0.016       568 (68.2)    561 (67.3)    0.135^†^   0.714
  Hyperlipidemia                             601 (69.6)    1317 (71.3)   0.825^†^   0.364       581 (69.7)    584 (70.1)    0.026^†^   0.873
  DM                                         261 (30.2)    600 (32.5)    1.385^†^   0.239       251 (30.1)    242 (29.1)    0.233^†^   0.629
  Smoking                                    478 (55.9)    987 (54.2)    0.707^†^   0.400       467 (56.1)    476 (57.1)    0.198^†^   0.656
  Family history                             213 (24.7)    455 (24.7)    0^†^       0.991       205 (24.6)    199 (23.9)    0.118^†^   0.732
  CVD                                        94 (10.9)     179 (9.7)     0.928^†^   0.335       93 (11.2)     89 (10.7)     0.099^†^   0.753
  PAD                                        24 (2.8)      72 (3.9)      2.156^†^   0.142       23 (2.8)      36 (4.3)      2.970^†^   0.085
  COPD                                       19 (2.2)      42 (2.3)      0.014^†^   0.904       17 (2.0)      14 (1.7)      0.296^†^   0.587
  OMI                                        274 (31.7)    483 (26.2)    9.110^†^   0.003       268 (32.2)    276 (33.1)    0.175^†^   0.676
  Previous PCI                               252 (29.2)    500 (27.1)    1.312^†^   0.252       242 (29.1)    263 (31.6)    1.253^†^   0.263
  Previous CABG                              37 (4.3)      82 (4.4)      0.033^†^   0.855       36 (4.3)      44 (5.3)      0.840^†^   0.359
  eGFR before PCI (ml·min^--1^·1.73m^--2^)   91.7 ± 14.9   92.4 ± 14.0   −1.139\*   0.255       91.6 ± 15.0   92.0 ± 14.3   −0.429\*   0.668
  Medication (cases)                                                                                                                   
   Aspirin                                   857 (99.3)    1818 (98.5)   3.203^†^   0.074       828 (99.4)    825 (99.0)    0.698^†^   0.404
   Clopidogrel                               856 (99.2)    1821 (98.6)   1.486^†^   0.223       826 (99.2)    821 (98.6)    1.331^†^   0.249
   Statin                                    836 (96.9)    1770 (95.9)   1.571^†^   0.210       806 (96.8)    797 (95.7)    1.336^†^   0.248
   β-blocker                                 790 (91.5)    1690 (91.5)   0^†^       0.994       764 (91.7)    765 (91.8)    0.008^†^   0.929
   Calcium antagonist                        402 (46.6)    869 (47.1)    0.057^†^   0.811       388 (46.6)    383 (46.0)    0.060^†^   0.806
   Nitrate                                   843 (97.7)    1792 (97.1)   0.817^†^   0.366       813 (97.6)    811 (97.4)    0.098^†^   0.755

Data are shown as mean ± SD or *n* (%). \**t* values; ^†^*χ*^2^ values. PSM: Propensity score matching; BMI: Body mass index; LVEF: Left ventricular ejection fraction; DM: Diabetes mellitus; CVD: Cerebral vascular disease; PAD: Peripheral artery disease; COPD: Chronic obstructive pulmonary disease; OMI: Old myocardial infarction; eGFR: Estimated glomerular filtration rate; G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; SD: Standard deviation.

###### 

Coronary angiography and percutaneous coronary intervention baseline data before and after propensity score matching

  Characteristics                         Before PSM   Statistics    *P*          After PSM    Statistics   *P*                     
  --------------------------------------- ------------ ------------- ------------ ------------ ------------ ------------ ---------- ---------
  Lesions involving LM                    25 (2.9)     42 (2.3)      0.942\*      0.332        24 (2.9)     26 (3.1)     0.082\*    0.774
  Lesions involving LAD                   761 (88.2)   1709 (92.6)   14.139\*     \<0.0001     733 (88.0)   743 (89.2)   0.594\*    0.441
  Lesions involving LCX                   170 (19.7)   236 (12.8)    22.066\*     \<0.0001     164 (19.7)   156 (18.7)   0.248\*    0.619
  Number of lesions treated               1.4 ± 0.6    1.3 ± 0.6     3.967^†^     \<0.0001     1.4 ± 0.6    1.4 ± 0.7    0.453^†^   0.650
  Number of stents                        2.0 ± 1.1    1.7 ± 0.9     7.097^†^     \<0.0001     2.0 ± 1.1    1.9 ± 1.1    0.791^†^   0.429
  Number of target vessel                                                                                                           
   Single vessel                          639 (74.0)   1513 (82.0)   24.490\*     \<0.0001     619 (74.3)   627 (75.3)   2.098\*    0.910
   Double vessel                          186 (21.6)   274 (14.8)    178 (21.4)   165 (19.8)                                        
   Triple vessel                          13 (1.5)     16 (0.9)      12 (1.4)     14 (1.7)                                          
   LM + single vessel                     4 (0.5)      10 (0.5)      4 (0.5)      4 (0.5)                                           
   LM + double vessel                     17 (2.0)     26 (1.4)      16 (1.9)     16 (1.9)                                          
   LM + triple vessel                     4 (0.5)      6 (0.3)       4 (0.5)      6 (0.7)                                           
   SVG + single vessel                    0            1 (0.1)       0            1 (0.1)                                           
  Normal origin of coronary artery        833 (96.5)   1757 (95.2)   2.533\*      0.111        805 (96.6)   793 (95.2)   2.208\*    0.137
  Right distribution of coronary artery   767 (88.9)   1614 (87.4)   1.152\*      0.283        741 (89.0)   728 (87.4)   0.973\*    0.324
  Transradial approach                    761 (88.2)   1645 (89.1)   0.513\*      0.474        736 (88.4)   729 (87.5)   0.277\*    0.599
  Pulling out sheath directly             750 (86.9)   1641 (88.9)   2.245\*      0.134        723 (86.8)   723 (86.8)   0\*        \>0.999
  IVUS application                        46 (5.3)     124 (6.7)     1.923\*      0.165        44 (5.3)     63 (7.6)     3.605\*    0.058
  IABP application                        6 (0.7)      19 (1.0)      0.718\*      0.397        6 (0.7)      12 (1.4)     2.022\*    0.155
  TIMI flow before PCI                                                                                                              
   0                                      146 (16.9)   228 (12.4)    16.115\*     0.001        148 (17.8)   127 (15.2)   2.209\*    0.530
   1                                      30 (3.5)     41 (2.2)      27 (3.2)     28 (3.4)                                          
   2                                      105 (12.2)   212 (11.5)    103 (12.4)   99 (11.9)                                         
   3                                      582 (67.4)   1365 (73.9)   555 (66.6)   579 (69.5)                                        
  TIMI flow after PCI                                                                                                               
   1                                      1 (0.1)      2 (0.1)       0.688\*      0.709        1 (0.1)      1 (0.1)      0.336\*    0.845
   2                                      7 (0.8)      10 (0.5)      7 (0.8)      5 (0.6)                                           
   3                                      855 (99.1)   1834 (99.3)   825 (99.0)   827 (99.3)                                        
  B2 or C lesions                         656 (76.0)   1336 (72.4)   4.006\*      0.045        635 (76.2)   623 (74.8)   0.467\*    0.494
  Moderate or severe calcification        158 (18.3)   289 (15.7)    3.004\*      0.083        148 (17.8)   148 (17.8)   0\*        \>0.999
  CTO lesions                             157 (18.2)   235 (12.7)    14.176\*     \<0.0001     153 (18.4)   132 (15.8)   1.867\*    0.172
  Ostial lesions                          123 (14.3)   281 (15.2)    0.436\*      0.509        118 (14.2)   136 (16.3)   1.505\*    0.220
  Bifurcation lesions                     147 (17.0)   382 (20.7)    5.012\*      0.025        140 (16.8)   167 (20.0)   2.911\*    0.088
  Thrombotic lesions                      19 (2.2)     32 (1.7)      0.698\*      0.404        18 (2.2)     17 (2.0)     0.029\*    0.864

Data were shown as mean ± SD or *n* (%). \**χ*^2^ values; ^†^*t* values. CAG: Coronary angiography; LAD: Left anterior descending artery; LCX: Left circumflex artery; LM: Left main artery; SVG: Saphenous vein graft; IVUS: Intravascular ultrasound; IABP: Intra-aortic balloon pump; TIMI: Thrombolysis in myocardial infarction; CTO: Chronic total occlusion; PCI: Percutaneous coronary intervention; SD: Standard deviation; G1-DES: First-generation drug-eluting stent; G2-DES: Second-generation drug-eluting stent; PSM: Propensity score matching.

Before PSM, the occurrence of MACE between G1-DES and G2-DES showed no significant difference (4.9% vs. 3.6%, *P* = 0.127), and neither were differences observed in the incidence of TV-MI (0.3% vs. 0.5%, *P* = 0.496), TVR (4.1% vs. 3.1%, *P* = 0.224), TLR (3.4% vs. 2.3%, *P* = 0.120), cardiogenic death (0.7% vs. 0.3%, *P* = 0.176), and bleeding events (6.7% vs. 7.5%, *P* = 0.480). The incidence of revascularization between G1-DES and G2-DES showed a trend of significant difference with a threshold *P* - value (8.6% vs. 6.7%, *P* = 0.084). The incidence of ST showed no difference (0.3% vs. 0.3%, *P* = 0.924). After PSM, the occurrence of MACE (4.8% vs. 4.0%, *P* = 0.399), TV-MI (0.2% vs. 0.7%, *P* = 0.156), TVR (4.1% vs. 3.1%, *P* = 0.293), TLR (3.5% vs. 2.5%, *P* = 0.251), cardiogenic death (0.6% vs. 0.5%, *P* = 0.738), ST (0.4% vs. 0.6%, *P* = 0.478), and bleeding events (6.2% vs. 8.3%, *P* = 0.109) between two groups did not significantly differ \[[Table 3](#T3){ref-type="table"}\].

###### 

Two-year outcomes before and after propensity score matching, *n* (%)

  Items                      Before PSM   *χ*^2^      *P*     After PSM   *χ*^2^     *P*                
  -------------------------- ------------ ----------- ------- ----------- ---------- ---------- ------- ---------
  MACE                       42 (4.9)     67 (3.6)    2.331   0.127       40 (4.8)   33 (4.0)   0.702   0.402
  MI                         16 (1.9)     31 (1.7)    0.105   0.746       15 (1.8)   15 (1.8)   0       \>0.999
  TV-MI                      3 (0.3)      10 (0.5)    0.464   0.496       2 (0.2)    6 (0.7)    2.010   0.156
  Revascularization          74 (8.6)     124 (6.7)   2.995   0.084       71 (8.5)   65 (7.8)   0.288   0.591
  TVR                        35 (4.1)     58 (3.1)    1.481   0.224       34 (4.1)   26 (3.1)   1.107   0.293
  TLR                        29 (3.4)     43 (2.3)    2.416   0.120       29 (3.5)   21 (2.5)   1.320   0.251
  All-cause death            9 (1.0)      16 (0.9)    0.200   0.655       8 (1.0)    8 (1.0)    0       \>0.999
  Cardiogenic death          6 (0.7)      6 (0.3)     1.828   0.176       5 (0.6)    4 (0.5)    0.112   0.738
  ST                         3 (0.3)      6 (0.3)     0.009   0.924       3 (0.4)    4 (0.5)    0.143   0.705
  Acute ST                   0            1 (0.1)     0       \>0.999     0          0                  
  Subacute ST                1 (0.1)      0           0       \>0.999     1 (0.1)    0          0       \>0.999
  Late ST                    1 (0.1)      0           0       \>0.999     1 (0.1)    0          0       \>0.999
  Very late ST               1 (0.1)      5 (0.3)     0.639   0.424       1 (0.1)    4 (0.5)    1.805   0.179
  Bleeding                   58 (6.7)     138 (7.5)   0.499   0.480       52 (6.2)   69 (8.3)   2.575   0.109
  Bleeding of BARC 2 and 3   18 (2.1)     58 (3.1)    2.406   0.121       17 (2.0)   25 (3.0)   1.563   0.211

MACE: Major adverse cardiovascular event; MI: Myocardial infarction; TV-MI: Target vessel-related myocardial infarction; TVR: Target vessel revascularization; TLR: Target lesion revascularization; ST: Stent thrombosis; BARC: Bleeding academic research consortium; PSM: Propensity score matching; G1-DES: First generation drug-eluting stent; G2-DES: Second generation drug-eluting stent.

Application of Kaplan--Meier survival analysis showed that G2-DES significantly improved TLR-free survival compared to G1-DES (96.6% vs. 97.9%, *P* = 0.049), and also a trend for G2-associated decrease in revascularization (92.0% vs. 93.8%, *P* = 0.082). There is a separative trend in MACE-free survival and TVR-free survival. Although no significant differences were found in all endpoints including bleeding events after PSM, we can still see a separative trend in MACE-free survival, revascularization-free survival, TVR-free survival, and TLR-free survival curves \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. After multivariate adjustment, there was only a trend for G1-associated increase in revascularization (hazard ratio: 1.28, 95% confidence interval: 0.95--1.72, *P* = 0.099), and no significance was found after PSM. Other endpoints, including bleeding events showed no significant differences after multivariate adjustment regardless of PSM between two groups \[[Table 4](#T4){ref-type="table"}\].

![Kaplan--Meier curve analysis before propensity score matching for 2-year follow-up of all-cause death (a), MI (b), revascularization (c), MACE (d), TV-MI (e), TVR (f), TLR (g), cardiogenic death (h), and ST (i). G2-DES significantly improved TLR-free survival compared to G1-DES, and also a trend for G1-associated increase in revascularization. There is a separative trend in MACE-free survival and TVR-free survival. G2-DES: Second-generation drug-eluting stents; G1-DES: First-generation drug-eluting stents; PSM: Propensity score matching; MI: Myocardial infarction; MACE: Major adverse cardiovascular event; TV-MI: Target vessel-related myocardial infarction; TLR: Target lesion revascularization; TVR: Target vessel revascularization; ST: Stent thrombosis.](CMJ-130-1654-g002){#F2}

![Kaplan--Meier curve analysis after propensity score matching for 2-year follow-up of all-cause death (a), MI (b), revascularization (c), MACE (d), TV-MI (e), TVR (f), TLR (g), cardiogenic death (h), and ST (i). Although no significant differences were found in all endpoints, there is a separative trend in MACE-free survival, revascularization-free survival, TVR-free survival and TLR-free survival curves after PSM. PSM: Propensity score matching; MI: Myocardial infarction; MACE: Major adverse cardiovascular event; TV-MI: Target vessel-related myocardial infarction; TLR: Target lesion revascularization; TVR: Target vessel revascularization; ST: Stent thrombosis.](CMJ-130-1654-g003){#F3}

###### 

Multivariate Cox proportional hazard regression analysis

  Items                         Before PSM          After PSM                       
  ----------------------------- ------------------- ----------- ------------------- -------
  MACE                          1.26 (0.85--1.87)   0.247       1.19 (0.75--1.89)   0.462
  MI                            1.00 (0.54--1.85)   0.997       0.97 (0.48--2.00)   0.940
  TV-MI                         0.62 (0.17--2.33)   0.478       0.31 (0.06--1.54)   0.151
  Revascularization             1.28 (0.95--1.72)   0.099       1.08 (0.77--1.51)   0.660
  TLR                           1.42 (0.88--2.29)   0.153       1.33 (0.76--2.33)   0.327
  TVR                           1.27 (0.83--1.94)   0.277       1.28 (0.76--2.13)   0.352
  All-cause death               1.12 (0.49--2.58)   0.786       1.03 (0.38--2.78)   0.951
  Cardiogenic death             1.68 (0.53--5.38)   0.381       1.08 (0.29--4.13)   0.906
  ST                            0.99 (0.24--4.05)   0.990       0.69 (0.15--3.10)   0.625
  Bleeding                      0.90 (0.66--1.22)   0.486       0.75 (0.52--1.08)   0.117
  Bleeding of BARC II and III   0.62 (0.36--1.07)   0.085       0.66 (0.35--1.22)   0.180

A trend for G1-associated increase in revascularization was found, while other endpoints showed no significantly differences. TV-MI: Target vessel-related myocardial infarction; TLR: Target lesion revascularization; TVR: Target vessel revascularization; ST: Stent thrombosis; *HR*: Hazard ratio; *CI*: Confidence interval; PSM: Propensity score matching; BARC: Bleeding academic research consortium; G1: First generation; MACE: Major adverse cardiovascular event; MI: Myocardial infarction.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Several clinical trials reached the conclusion that G2-DES reduced ST, MI, and TLR risks compared to G1-DES.\[[@ref9][@ref12]\] The SCAAR registry showed, in a 2-year follow-up of 94384 consecutively enrolled CAD patients, that G2-DES reduced the incidence of in-stent restenosis (ISR) by 38%, definite ST by 43%, and mortality by 23% compared to G1-DES.\[[@ref18]\] The Endeavor trial and the SPIRIT trials I--IV collectively concluded that (1) G2-DES were superior to BMS in reducing ISR and revascularization risk, and (2) G2-DES were superior to G1-DES in reducing risks of ISR, ST, TV-MI, and cardiogenic death.\[[@ref1][@ref8][@ref10][@ref11]\] A 2012 meta-analysis showed that, compared to G1-DES, G2-DES lowered the rate of definite ST during both 1- and 2-year follow-ups.\[[@ref19]\] Some evidence supporting the superiority of G2-DES came from a recent large meta-analysis showing significantly better efficacy and safety of G2-DES compared to G1-DES.\[[@ref16]\] In light of these results, we hypothesized that G2-DES would show significantly improved efficacy and safety profiles in Chinese SCAD patients during a 2-year follow-up.

In this retrospective analysis, we draw several points: (1) Though all the event rates showed no significant differences, G2-DES improved TLR-free survival compared to G1-DES, and revascularization-free survival curve showed a trend of G2-asscociated improvement. The advantage was diminished by removing effects of baseline factors. (2) G1-DES was only associated with a trend of increase in revascularization risk and was not an independent predictor of worse medium-term prognosis compared with G2-DES. (3) G1-DESs were as safety as G2-DESs in this large Chinese cohort of real-world patients.

Although the conclusion does not go against the findings from the above-mentioned trials, the differences are not as significant as we expected. One possible reason may due to the low rates of coronary adverse events in SCAD patients compared to all-comer study. The all-cause mortality in this study was about 1% while in SOUT OUT IV trial the all-cause mortality was around 4%.\[[@ref20]\] Pathophysiology of SCAD involves stable plaques, which have thicker fibrous caps, smaller lipid cores, more collagen and smooth muscle cells, and fewer macrophages.\[[@ref21][@ref22]\] As such, stable plagues seldom rupture and lead to the acute coronary thrombus. In addition, this is a study performed in a single center with advanced PCI technology and standard secondary prevention medication, both leading to rates of adverse coronary events lower than those reported elsewhere. Therefore, the benefits of G2-DES would be too difficult to detect without enormous sample sizes, probably covering more years or multicenter patients. It may be for this reason that we only see a trend of separating-curves with critical *P* values. Meanwhile, follow-up of our study may too short to find the difference. The Kaplan--Meier curves of MACE, revascularization, TVR, TLR may significantly separate during subsequent follow-up. This study may simply be underpowered for detection of advantage in the efficacy of G2-DES. In light of these considerations, it is arguable whether the differences we found are underestimated.

Furthermore, G1-DESs were found the same safety as G2-DESs in definite/probable ST. In SORT OUT IV trial, the definite/probable ST showed no difference while definite ST showed significant increase in sirolimus-eluting stent group at 18 months.\[[@ref20]\] One possible reason may be that long-term follow-up should be conducted. Ten-year outcomes of SORT OUT II trial showed a steady annual rate of 1.3% in definite, probable and possible ST after the 1^st^ year.\[[@ref23]\] Patients received G1-DES need for continuous surveillance for ST.

Admittedly, there are several limitations in this study. (1) DES within the same generation is not directly compared to each other, the heterogeneity of efficacy and safety for different DESs within each generation may confound study outcomes to a certain extent. (2) The nature of nonrandomized comparisons cannot be overlooked. Although PSM was applied to remove effects of differing baseline factors, the results were still influenced by other characteristics not including in the study, such as SNYTAX scores. (3) All secondary prevention drugs in baseline data referred to medication at discharge definitely. Medication compliance of every patient during follow-up may bring about bias.

Nevertheless, these results will help to guide clinical decision making by providing evidence that, as far as abroad groups concerned, the performance of first- and second-generation stents differs in their efficacy profiles. In our single-center study, G2-DES is more than 2-fold more prevalent than G1-DES for SCAD patients undergoing PCI during 2013. Although application of G1-DES declines rapidly in Third Grade Class A Hospital, it is still holding part of the market of local hospitals throughout our country. The results were driven from the tertiary hospital with high PCI volumes and skilled operators. Although it cannot be extrapolated to local hospitals with low PCI volumes and unskilled operators, it still provides some confidence that G1-DESs are not so bad. Cost performance may be taken into consideration by poor patients. Other indications also are objective, such as limited choices of DES types in basic hospital or on insurance list. Prognosis is decided by many factors, not only the stent type. At least, G1-DES application is not an independent predictor of worse medium-term outcomes compared with G2-DES. Overall, a better grasp of therapeutic benefits of these G2-DES would have deep economic effects on SCAD patients who undergo PCI, especially in developing countries like China.\[[@ref24][@ref25]\]
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